Pfizer Paid Out $14.6 Billion in Dividends Over the Last 18 Months. Can It Keep This Up Through the Patent Cliff?

Pfizer distributed $14.6 billion in dividends over the past 18 months while carrying a dividend payout ratio above 130%, raising sustainability questions as key patents expire in 2027-2028. The stock currently offers a 7% yield, but the company is paying out more in dividends than it earns—a red flag for income-focused investors.

The pharmaceutical giant faces a patent cliff with major drugs losing exclusivity within the next few years, compressing its revenue base just as dividend obligations remain elevated. Management has signaled dividend preservation as a priority, and Pfizer maintains cash reserves plus access to debt markets to support continued payouts even if earnings remain pressured.

The pipeline of new drug candidates appears limited relative to the scale of upcoming patent expirations, creating a narrow path for organic growth to close the earnings gap. The company will likely need either blockbuster approvals or significant cost restructuring to bring the payout ratio back to sustainable levels.